Dr. Conor O'Toole:

No, I do not have those figures. I was talking more on a company-by-company basis. There would be a particular pharmaceutical company that would have a set of global sales broken down by how much it sells in the US and how much it sells in other countries. It will have to make the calculation as to whether, given the tariff rate, it would make more sense to produce the stuff it wants to sell to US consumers in the US or produce it somewhere else and export it to the US. It really will be a company-by-company assessment that will have to be undertaken depending on whether or not pharmaceuticals gets covered and depending on what the tariff would be if it comes into-----